Stimulant therapy for ADHD depends heavily on how quickly a dose takes effect and how long it lasts. Azstarys (serdexmethylphenidate and dexmethylphenidate) approached that problem through prodrug chemistry.
The capsule combines immediate-release dexmethylphenidate with serdexmethylphenidate, a prodrug converted to active drug in the lower gastrointestinal tract, delivering early onset from one component and extended coverage from the other. It is taken once daily for ADHD in patients 6 years and older.
Azstarys remains marketed as a Schedule II controlled substance without generic competition. Its prodrug design is the main differentiator in a mature methylphenidate market, making it relevant to tracking duration-focused and abuse-deterrent ADHD formulations.
